Last reviewed · How we verify
Sufentanil epidural bolus
Sufentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central and peripheral nervous system to produce analgesia and sedation.
Sufentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central and peripheral nervous system to produce analgesia and sedation. Used for Acute postoperative pain management via epidural administration, Labor pain analgesia.
At a glance
| Generic name | Sufentanil epidural bolus |
|---|---|
| Sponsor | University of Genova |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain management, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sufentanil activates mu-opioid receptors, which are G-protein coupled receptors involved in pain modulation and emotional responses to pain. When administered epidurally as a bolus, it diffuses across the dura mater to act on opioid receptors in the spinal cord and brain, providing rapid onset analgesia. It is approximately 5-10 times more potent than fentanyl.
Approved indications
- Acute postoperative pain management via epidural administration
- Labor pain analgesia
Common side effects
- Respiratory depression
- Hypotension
- Pruritus
- Nausea and vomiting
- Urinary retention
- Sedation
Key clinical trials
- Effect of the PIEB Versus CEI on the Quality of Postoperative Recovery in Patients Undergoing VATS Lobectomy (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Regional Anesthesia Techniques in Breast Surgery (NA)
- Rhomboid Intercostal Block with Subserratus Plane Block in Bariatric Surgery (NA)
- PIEB-PCEA Versus CEI-PCEA for Labor Analgesia in Nulliparous (NA)
- Pharmacokinetics of Sufentanil After Epidural Administration
- PIEB vs CEI for Labor Analgesia: An MLAC Study (PHASE4)
- Study Comparing Dural Puncture Epidural With Epidural and Combined Spinal Epidural Anesthesia for Obstetric Analgesia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil epidural bolus CI brief — competitive landscape report
- Sufentanil epidural bolus updates RSS · CI watch RSS
- University of Genova portfolio CI